Harvard Bioscience (HBIO) Current Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Current Leases data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Current Leases rose 9.37% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 9.37% YoY) and the FY2025 annual result came in at $1.5 million, up 31.69% from the prior year.
• Current Leases rose to $1.6 million in Q1 2026 per HBIO's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Leases topped out at $2.2 million in Q1 2022 and bottomed at $1.1 million in Q2 2024.
• The 5-year median for Current Leases is $1.5 million (2025), against an average of $1.7 million.
• The widest annual swing landed in 2024, when Current Leases sank 50.21%; it then soared 37.33% in 2025.
• Tracing HBIO's Current Leases over 5 years: stood at $2.1 million in 2022, then tumbled by 33.68% to $1.4 million in 2023, then slipped by 18.22% to $1.2 million in 2024, then soared by 31.69% to $1.5 million in 2025, then gained by 1.77% to $1.6 million in 2026.
• Per Business Quant, the three latest HBIO Current Leases figures stand at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025).

Peer Comparison